Changes in colonic enteroendocrine cells of patients with irritable bowel syndrome following fecal microbiota transplantation

References

• Moran GW, Leslie FC, Levison SE, et al. Enteroendocrine cells: neglected players in gastrointestinal disorders? Therap Adv Gastroenterol. 2008;1(1):51–60.
   PubMedGoogle Scholar
• Moran-Ramos S, Tovar AR, Torres N. Diet: friend or foe of enteroendocrine cells-how it interacts with enteroendocrine cells. Adv Nutr. 2012;3(1):8–20.
   PubMed Web of Science ®Google Scholar
• Sternini C, Anselmi L, Rozengurt E. Enteroendocrine cells: a site of 'taste' in gastrointestinal chemosensing. Curr Opin Endocrinol Diabetes Obes. 2008;15(1):73–78.
   PubMed Web of Science ®Google Scholar
• El-Salhy M, Mazzawi T, Hausken T, et al. Interaction between diet and gastrointestinal endocrine cells. Biomed Rep. 2016;4(6):651–656.
   PubMedGoogle Scholar
• Mazzawi T, El-Salhy M. Effect of diet and individual dietary guidance on gastrointestinal endocrine cells in patients with irritable bowel syndrome (review). Int J Mol Med. 2017;40(4):943–952.
   PubMed Web of Science ®Google Scholar
• Bauer PV, Hamr SC, Duca FA. Regulation of energy balance by a gut-brain axis and involvement of the gut microbiota. Cell Mol Life Sci. 2016;73(4):737–755.
   PubMed Web of Science ®Google Scholar
• Mazzawi T, Hausken T, Gundersen D, et al. Dietary guidance normalizes large intestinal endocrine cell densities in patients with irritable bowel syndrome. Eur J Clin Nutr. 2016;70(2):175–181.
   PubMed Web of Science ®Google Scholar
• El-Salhy M, Grimelius L, Wilander E, et al. Immunocytochemical identification of polypeptide YY (PYY) cells in the human gastrointestinal tract. Histochemistry. 1983;77(1):15–23.
   PubMedGoogle Scholar
• Spangeus A, Forsgren S, el-Salhy M. Does diabetic state affect co-localization of peptide YY and enteroglucagon in colonic endocrine cells? Histol Histopathol. 2000;15(1):37–41.
   PubMed Web of Science ®Google Scholar
• El-Salhy M, Gundersen D, Ostgaard H, et al. Low densities of serotonin and peptide YY cells in the Colon of patients with irritable bowel syndrome. Dig Dis Sci. 2012;57(4):873–878.
   PubMed Web of Science ®Google Scholar
• Mazzawi T, Gundersen D, Hausken T, et al. Increased chromogranin a cell density in the large intestine of patients with irritable bowel syndrome after receiving dietary guidance. Gastroenterol Res Pract. 2015;2015:823897.
   PubMed Web of Science ®Google Scholar
• Hong SN, Rhee PL. Unraveling the ties between irritable bowel syndrome and intestinal microbiota. World J Gastroenterol. 2014;20(10):2470–2481.
   PubMed Web of Science ®Google Scholar
• Carroccio A, Brusca I, Mansueto P, et al. A cytologic assay for diagnosis of food hypersensitivity in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol. 2010;8(3):254–260.
   PubMed Web of Science ®Google Scholar
• Ohman L, Simren M. Intestinal microbiota and its role in irritable bowel syndrome (IBS). Curr Gastroenterol Rep. 2013;15(5):323.
   PubMedGoogle Scholar
• Kassinen A, Krogius-Kurikka L, Makivuokko H, et al. The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology. 2007;133(1):24–33.
   PubMed Web of Science ®Google Scholar
• Greiner TU, Backhed F. Microbial regulation of GLP-1 and L-cell biology. Mol Metab. 2016;5(9):753–758.
   PubMed Web of Science ®Google Scholar
• Everard A, Lazarevic V, Derrien M, et al. Responses of gut microbiota and glucose and lipid metabolism to prebiotics in genetic obese and diet-induced leptin-resistant mice. Diabetes. 2011;60(11):2775–2786.
   PubMed Web of Science ®Google Scholar
• Neyrinck AM, Van Hee VF, Piront N, et al. Wheat-derived arabinoxylan oligosaccharides with prebiotic effect increase satietogenic gut peptides and reduce metabolic endotoxemia in diet-induced obese mice. Nutr Diabetes. 2012;2:e28.
   PubMed Web of Science ®Google Scholar
• Mazzawi T, Lied GA, Sangnes DA, et al. The kinetics of gut microbial community composition in patients with irritable bowel syndrome following fecal microbiota transplantation. PLoS One. 2018;13(11):e0194904.
   PubMed Web of Science ®Google Scholar
• Mazzawi T, Eikrem Ø, Lied GA, et al. Abnormal uroguanylin immunoreactive cells density in the duodenum of patients with Diarrhea-Predominant irritable bowel syndrome changes following fecal microbiota transplantation. Gastroenterol Res Pract. 2020;2020:3520686.
   PubMed Web of Science ®Google Scholar
• Mazzawi T, El-Salhy M, Lied GA, et al. The effects of fecal microbiota transplantation on the symptoms and the duodenal neurogenin 3, musashi 1, and enteroendocrine cells in patients with Diarrhea-Predominant irritable bowel syndrome. Front Cell Infect Microbiol. 2021;11:524851.
   PubMed Web of Science ®Google Scholar
• Johnsen PH, Hilpusch F, Cavanagh JP, et al. Faecal microbiota transplantation versus placebo for moderate-to-severe irritable bowel syndrome: a double-blind, randomised, placebo-controlled, parallel-group, single-Centre trial. Lancet Gastroenterol Hepatol. 2018;3(1):17–24.
   PubMed Web of Science ®Google Scholar
• el-Salhy M, Sandstrom O, Nasstrom E, et al. Application of computer image analysis in endocrine cell quantification. Histochem J. 1997;29(3):249–256.
   PubMedGoogle Scholar
• El-Salhy M, Gilja OH, Gundersen D, et al. Endocrine cells in the ileum of patients with irritable bowel syndrome. WJG. 2014;20(9):2383–2391.
   PubMed Web of Science ®Google Scholar
• El-Salhy M, Gilja OH, Gundersen D, et al. Endocrine cells in the oxyntic mucosa of the stomach in patients with irritable bowel syndrome. WJGE. 2014;6(5):176–185.
   Google Scholar
• El-Salhy M, Gundersen D, Hatlebakk JG, et al. Abnormal rectal endocrine cells in patients with irritable bowel syndrome. Regul Pept. 2014;188:60–65.
   PubMed Web of Science ®Google Scholar
• El-Salhy M, Hatlebakk JG, Hausken T. Reduction in duodenal endocrine cells in irritable bowel syndrome is associated with stem cell abnormalities. World J Gastroenterol. 2015;21(32):9577–9587.
   PubMed Web of Science ®Google Scholar
• Mazzawi T, El-Salhy M. Dietary guidance and ileal enteroendocrine cells in patients with irritable bowel syndrome. Exp Ther Med. 2016;12(3):1398–1404.
   PubMed Web of Science ®Google Scholar
• Mazzawi T, El-Salhy M. Changes in small intestinal chromogranin A-immunoreactive cell densities in patients with irritable bowel syndrome after receiving dietary guidance. Int J Mol Med. 2016;37(5):1247–1253.
   PubMed Web of Science ®Google Scholar
• Mazzawi T, El-Salhy M. Changes in duodenal enteroendocrine cells in patients with irritable bowel syndrome following dietary guidance. Exp Biol Med (Maywood)). 2017;242(13):1355–1362.
   PubMed Web of Science ®Google Scholar
• Mazzawi T, Gundersen D, Hausken T, et al. Increased gastric chromogranin a cell density following changes to diets of patients with irritable bowel syndrome. Mol Med Rep. 2014;10(5):2322–2336.
   PubMed Web of Science ®Google Scholar
• Mazzawi T, Hausken T, Gundersen D, et al. Effect of dietary management on the gastric endocrine cells in patients with irritable bowel syndrome. Eur J Clin Nutr. 2015;69(4):519–524.
   PubMed Web of Science ®Google Scholar
• Hustoft TN, Hausken T, Ystad SO, et al. Effects of varying dietary content of fermentable short-chain carbohydrates on symptoms, fecal microenvironment, and cytokine profiles in patients with irritable bowel syndrome. Neurogastroenterol Motility. 2017;29(4). DOI:https://doi.org/10.1111/nmo.12969.
   PubMed Web of Science ®Google Scholar
• El-Salhy M, Gilja OH, Gundersen D, et al. Interaction between ingested nutrients and gut endocrine cells in patients with irritable bowel syndrome (review). Int J Mol Med. 2014;34(2):363–371.
   PubMed Web of Science ®Google Scholar
• Wiedenmann B, Huttner WB. Synaptophysin and chromogranins/secretogranins-widespread constituents of distinct types of neuroendocrine vesicles and new tools in tumor diagnosis. Virchows Arch B Cell Pathol Incl Mol Pathol. 1989;58(2):95–121.
   PubMedGoogle Scholar
• Taupenot L, Harper KL, O'Connor DT. The chromogranin-secretogranin family. N Engl J Med. 2003;348(12):1134–1149.
   PubMed Web of Science ®Google Scholar
• El-Salhy M, Lomholt-Beck B, Hausken T. Chromogranin a as a possible tool in the diagnosis of irritable bowel syndrome. Scand J Gastroenterol. 2010;45(12):1435–1439.
   PubMed Web of Science ®Google Scholar
• Deftos LJ. Chromogranin A: its role in endocrine function and as an endocrine and neuroendocrine tumor marker. Endocr Rev. 1991;12(2):181–187.
   PubMed Web of Science ®Google Scholar
• Gershon MD, Tack J. The serotonin signaling system: from basic understanding to drug development for functional GI disorders. Gastroenterology. 2007;132(1):397–414.
   PubMed Web of Science ®Google Scholar
• Gershon MD. Plasticity in serotonin control mechanisms in the gut. Curr Opin Pharmacol. 2003;3(6):600–607.
   PubMed Web of Science ®Google Scholar
• Gershon MD. 5-Hydroxytryptamine (serotonin) in the gastrointestinal tract. Curr Opin Endocrinol Diabetes Obes. 2013;20(1):14–21.
   PubMedGoogle Scholar
• Gershon MD. Serotonin is a sword and a shield of the bowel: serotonin plays offense and defense. Trans Am Clin Climatol Assoc. 2012;123:268–280. discussion 80.
   PubMedGoogle Scholar
• Tack JF, Janssens J, Vantrappen G, et al. Actions of 5-hydroxytryptamine on myenteric neurons in guinea pig gastric antrum. Am J Physiol. 1992;263(6 Pt 1):G838–46.
   PubMed Web of Science ®Google Scholar
• Michel K, Sann H, Schaaf C, et al. Subpopulations of gastric myenteric neurons are differentially activated via distinct serotonin receptors: projection, neurochemical coding, and functional implications. J Neurosci. 1997;17(20):8009–8017.
   PubMed Web of Science ®Google Scholar
• Tack J, Coulie B, Wilmer A, et al. Influence of sumatriptan on gastric fundus tone and on the perception of gastric distension in man. Gut. 2000;46(4):468–473.
   PubMed Web of Science ®Google Scholar
• Gershon MD. Review article: roles played by 5-hydroxytryptamine in the physiology of the bowel. Aliment Pharmacol Ther. 1999;13(Suppl 2):15–30.
   PubMed Web of Science ®Google Scholar
• Gershon MD, Wade PR, Kirchgessner AL, et al. 5-HT receptor subtypes outside the central nervous system. Roles in the physiology of the gut. Neuropsychopharmacology. 1990;3(5-6):385–395.
   PubMed Web of Science ®Google Scholar
• El-Salhy M, Gundersen D, Gilja OH, et al. Is irritable bowel syndrome an organic disorder? World J Gastroenterol. 2014;20(2):384–400.
   PubMed Web of Science ®Google Scholar
• El-Salhy M, Mazzawi T, Gundersen D, et al. The role of peptide YY in gastrointestinal diseases and disorders (review). Int J Mol Med. 2013;31(2):275–282.
   PubMed Web of Science ®Google Scholar